Diabetic Macular Edema Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Diabetic Macular Edema Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Macular Edema - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Diabetic Macular Edema (Metabolic Disorders) pipeline landscape.

Diabetic macular edema (DME) occurs when blood vessels in the retina of patients with diabetes begin to leak into the macula, the part of the eye responsible for detailed central vision. Common symptoms of DME are blurry vision, floaters, double vision, and eventually blindness if it goes untreated. Risk factors include age and diabetes.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Diabetic Macular Edema - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Diabetic Macular Edema (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Diabetic Macular Edema (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Diabetic Macular Edema and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 12, 25, 18, 3, 61, 10 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.

Diabetic Macular Edema (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note:Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

• The pipeline guide provides a snapshot of the global therapeutic landscape of Diabetic Macular Edema (Metabolic Disorders).
• The pipeline guide reviews pipeline therapeutics for Diabetic Macular Edema (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Diabetic Macular Edema (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Diabetic Macular Edema (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Diabetic Macular Edema (Metabolic Disorders)

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Diabetic Macular Edema (Metabolic Disorders).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Diabetic Macular Edema (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies Mentioned
Companies Mentioned

3SBio Inc
4D Molecular Therapeutics Inc
Aadi Bioscience Inc
Abpro Corp
Aciont Inc
Aerie Pharmaceuticals Inc
Aldeyra Therapeutics Inc
Allegro Ophthalmics LLC
Allgenesis Biotherapeutics Inc
AmMax Bio Inc
Ampio Pharmaceuticals Inc
ANBITION Srl
Apexian Pharmaceuticals Inc
Araim Pharmaceuticals Inc
Ascentage Pharma Group International
AsclepiX Therapeutics Inc
Ashvattha Therapeutics LLC
AskGene Pharma Inc
Avirmax Inc
BetaStem Therapeutics Inc
Bio-Thera Solutions Ltd
BioCryst Pharmaceuticals Inc
Cell Care Therapeutics Inc
Celltrion Inc
Celon Pharma SA
Chengdu Kanghong Pharmaceuticals Group Co Ltd
Chiome Bioscience Inc
Clearside BioMedical Inc
Curacle Co Ltd
Drive Therapeutics LLC
Elasmogen Ltd
Eluminex Biosciences Ltd
Everglades Biopharma LLC
Exonate Ltd
EyeGene Inc
F. Hoffmann-La Roche Ltd
Gene Signal International SA
GlaxoSmithKline Plc
Graybug Vision Inc
Guangdong Zhongsheng Pharmaceutical Co Ltd
Huabo Biopharm (Shanghai) Co Ltd
Huadong Medicine Co Ltd
Ikarovec Ltd
Innovent Biologics Inc
Isarna Therapeutics GmbH
Johnson & Johnson
Kala Pharmaceuticals Inc
Kalos Therapeutics Inc
Kalvista Pharmaceuticals Inc
Kanaph Therapeutics Inc
Kiora Pharmaceuticals Inc
Kodiak Sciences Inc
Kowa Co Ltd
Kubota Vision Inc
Kuur Therapeutics Ltd
Laboratorios Sophia SA de CV
Luye Pharma Group Ltd
Mabion SA
Mabwell Shanghai Bioscience Co Ltd
Molecular Partners AG
NeuMedics Inc
Novartis AG
Novelty Nobility Inc
Noveome Biotherapeutics Inc
Oak Hill Bio Inc
OccuRx Pty Ltd
Ocugen Inc
Ocular Therapeutix Inc
Oculis SA
OcuNexus Therapeutics Inc
OcuTerra Therapeutics Inc
Opthea Ltd
Outlook Therapeutics Inc
Oxular Ltd
Oxurion NV
PanOptica Inc
Phanes Therapeutics Inc
PharmAbcine Inc
Pleryon Therapeutics Ltd
Profarma
Qilu Pharmaceutical Co Ltd
Rebio Technologies Ltd
Regeneron Pharmaceuticals Inc
RemeGen Co Ltd
Rezolute Inc
RiniSight Inc
Ripple therapeutics Corp
Samsung Bioepis Co Ltd
Semathera Inc
Senju Pharmaceutical Co Ltd
Shanghai SIMR Biotech Co Ltd
Surrozen Inc
Suzhou Stainwei Biotech Inc
Targeted Therapy Technologies LLC
Theravance Biopharma Inc
Uni-Bio Science Group Ltd
Unity Biotechnology Inc
Verseon Corp
Xbrane Biopharma AB
YD Life Science Co
Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd